Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Those numbers come from the analysis I linked. (this) That analysis is still pertinent, but I'll add the disclaimer here that in the weeks since, we've learned that all the source filings are still unaudited. (Even the ones that omitted the "unaudited" label on page 1.)
All outstanding debt of the Company flowed to its subsidiary, now known as Robustomed, Inc. This means there are no outstanding convertible debt pieces of ENZC common equity, and that has been the case since November 30, 2020. This has been disclosed in all filings made on OTC (both annual and quarterly) since that date.
If all conversions to common stock were enacted, existing common stock restrictions removed, and warrants exercised this very moment, I am totaling:
380,289,565 restricted common flipped to Unrestricted.
4,471,800,000 from Series B conversions.
94,107,800 from Series C conversions.
176,332,400 from warrants > Series C > Common.
188,215,600 from purchased warrants.
unknown amount from company insiders stock options.
unknown amount from Series E conversions if these have any conversion pathway to common.
unknown amount from derivative liability conversions.
unknown amount from crowdfunded notes > Series D > Common if such a pathway exists.
Which comes to 5,310,745,365 Common shares PLUS all of the unknowns.
Obviously, it is not realistic for this to happen all at once, but note that the potential for future dilution is there.
Excellent post, thanks for the reality check!
It's fun to dream about what the NDA may be about, but all we really seem to know is that an NDA most likely exists. Disclosing the NDA vicariously through Hicks is a little odd. Hicks may not know what it's about either - probably he's just telling us what ENZC told him. Tom has been tweeting stuff like #equity and #specialsituations for awhile. Chandra is on record about the company nearing completion of the audit, submitting documents for uplisting, bringing IPF Immune to "big and small" retailers, and starting trials in Africa. There's been no word ENZC has changed its direction, and all of these hashtags and statements are influencing people's investment decisions, so hopefully there's something we investors will find meaningful behind the NDA.
That would be fantastic!! Haha :)
Interesting assessment. With all the shakedowns, short selling, bouncy corrections and flippers this year and last, I doubt MMs have missed an opportunity to accumulate shares. Retail's definitely holding a good chunk, but 2.8 billion outstanding is a lot of shares.
I bought a few more after learning of the NDA, because the NDA seems more concrete than the stuff Tom and Chandra keep tweeting, but I still see my money being at high risk since ENZC has been over promising and under delivering for many months. People are hopeful the NDA is something huge, but if the news drops and it's not something huge, I imagine share price will take a hit. (That would be social media's fault for hyping too hard, but still.)
Since the little man knows, be careful to take profits if news drops and this runs! There's bound to be flippers ready to sell the news. I imagine some folks may take the opportunity to liquidate and walk away, if they've been bagholding for a few years. There's 380 million restricted shares already issued that can be flipped to unrestricted and sold at any time. There also appear to be up to 5 billion common shares that may eventually be issued, due to ENZC's convertible notes, and likely more yet to be accounted for due to missing information in the filings - the safeguard for now is that the O/S is close to maxed out, so there's unlikely to be too many conversions without restructuring (probably a reverse split). If tides turn and there's money to be made, those Preferred shareholders will want a piece of the pie.
It all amounts to what I anticipate will be a strong selling pressure in the months ahead - and that can be counteracted by strong buying pressure if the company opens new doors with its NDA & operations.
Agreed, and you make an astute point.
But considering that Hicks wants to interview Chandra and Co. AFTER the NDA is lifted tells me that a buyout is not likely, since there would be no reason to interview anyone from ENZC after that
Yeah I may be wrong on that part. Added a disclaimer.
Makes sense - if MMs are prone to shake the tree, and if they have a pretty safe bet that there will be radio silence from ENZC through at least part of July, they have room to play a lot of games.
On the retail side, the word's out and social media won't forget it anytime soon. Will be interesting to see if retail can supply enough buying pressure to keep this from dropping below the high 5's.
If you follow charts, this is a week bulls need to answer to keep this from falling down a level. Good start today.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169051403
Don't forget to lock up your shares with some high Good-Til-Cancelled sell orders so MM's can't borrow them to short! :)
(If that's how that works)
The NDA is the most concrete thing I've seen in awhile from ENZC. Frustrating that it's coming vicariously through James Hicks instead of the company telling us directly. 'Coming in July' could be up to 60 days (36 trading days) from now, so MMs may shake the tree a couple times before then. Any news big enough for an NDA probably makes the current price range a bargain buy.
I am watching on stocktwits and the webull official twitter. No word on either, but the good news is the price movement so far just ate the last three days of short profits. Hopefully they're tempted to cover.
Why do you think the SEC would stick their nose in here?
Good info, thanks!
It appears Tom's pretty good at what he does, and he seems to have a track record of helping separate investors from their money. So yes it's a head scratcher why ENZC would want him helping with PR and social presence.
That's a question we all wish we could answer.
ENZC recently reported an accumulated deficit of $29,533,234 and has some ongoing legal stuff (at least three active lawsuits) to resolve. With the share price steadily fading, if they can't get a revenue stream through products like IPF Immune, they might be open minded to a buyout offer if one came along. Financing is also a reasonable possibility if the deal is sweet enough for equity partners (Samsung?) who believe in their tech.
When? Nobody knows. ENZC said in the Going Concern in recent filings that it expects to be able to operate on its own at least through Q1 2023.
ENZC's pattern in the last few quarters has been to raise capital by selling Series E Convertible Preferred and Series C Convertible Preferred stocks. They're nearly out of room to facilitate conversions or do their own dilution, with the total Outstanding Shares approaching total Authorized Shares, but as long as the market supports it, they could reverse split and carry out another round of dilution to keep future operations sufficiently funded.
Regarding your question about the WeFunder SAFE and turning that into ENZC shares, the SAFE notes are part of the Crowdfunding Convertible Notes reported in ENZC's fillings. Look on page 18 of this filling to see your options.
https://www.otcmarkets.com/otcapi/company/financial-report/327932/content
From the same report:
Since the underlying obligation to the investors is a BioClonetic obligation as it relates to a sale of the company and capital raises at the Company believes that neither of these scenario’s will never happen,
It's a real possibility. I'd still expect to see them give a status report on the stuff we already know about. (audit, ipf immune retailers, Africa)
Also be aware of wash sales if planning to buy back in. Selling at a loss, and buying shares of the same company within 30 days prior or after the loss - the loss might not be tax deductible.
https://www.investopedia.com/terms/w/washsalerule.asp
ENZC jumps around a fair bit and there always seems to be imminent news in the pipeline, so whatever strategy you pick, be sure to know your reasons.
TA and chart: This week closed at the edge of the bottom bollinger band and the low end of the candle. Next week it's important that bulls try and rally, because the momentum is currently downward and this is the bollinger lowband retest which may result in a breakdown next week if bears increase selling pressure unchecked. RSI is a cool 38.8, and 35ish has been acting like the bottom on the weekly, so there's room for a lot more selling and downward movement from here.
More optimistically, the bollinger bands are narrow and conditions are favorable for these levels to act as a double bottom to support a reversal if we can get a significant catalyst to reenergize bulls. MM's may not be taking many shorts at these levels until it's clear which way the market will move. Hopefully ENZC will deliver good news early week.
GLTA and have a nice weekend!
Weekly chart, purple line is 200 week moving average:
Here's some other Tom Nelson tweets:
May 13 2022 $ENZC #IPFIMMUNE #products #news #equity #UPDATE #retailers #StocksToBuy #Reuters #pharmacy
Mar 21 2022 $ENZC Month of March is not over yet. Big updates coming..Keep it on your radar..#Equity #AnnualReport #specialsituations #cure #immune
Mar 16 2022 $ENZC one word #cure...
Mar 12 2022 $ENZC has more updates coming...#Production #technology #Equity #specialsituations #uplist #stockstowatch #Bullish
Feb 14 2022 $ENZC huge long term play, special situations, company is growing with big upside..Keep on your radar..It's all well planned...
Dec 1 2021 $ENZC going to be an eye opener here real soon....
Nov 4 2021 $ENZC Believe me it only gets better from here on...
Oct 7 2021 $ENZC has big news today. Signs of institutional level, partnerships , uplist and ready for takeoff...
Sep 30 2021 $ENZC is institutional level ready...Buy Side Analyst would be key indicator...
Sep 28 2021 $ENZC getting ready for the institutional level...
Jun 25 2021 $ENZC peeps this will turn into a monster ...#stock #stocks #trading #OTC #OTCStocks
And a quote from elsewhere:
I see that $enzc has hired Tom Nelson, husband of the CEO of $cbdl, to do PR. $cbdl has added almost 15B shares to the market in 2021. Their Q1 financials showed $25k in revenue but CEO made $60K and they had $1M+ in marketing expenses? Interesting. I will be following this.
May 11 2021
I see that $enzc has hired Tom Nelson, husband of the CEO of $cbdl, to do PR. $cbdl has added almost 15B shares to the market in 2021. Their Q1 financials showed $25k in revenue but CEO made $60K and they had $1M+ in marketing expenses? Interesting. I will be following this.
— Donny Stock Trader (@DTradee) May 11, 2021
I tried that strategy for awhile. It's a good way to save money (unless the big news drops while I'm cashed out) but I also have to be really good at picking a reentry, or have iron-willed patience to not take a bad reentry if it suddenly starts to run. Without micromanaging things, and waffling whether to get back in or wait longer, I wasn't making a ton of headway.
Other than my long core, I did sell a bunch around .15 last year and haven't reinvested that money in ENZC yet. So far that's been working out - I could rebuy for almost triple now. But when this moves it can move pretty fast, so if I'm caught off guard I might be forced to buy back in at .16+. (I'd still rather do it this way to control the risk, since the current downtrend is real, the company has made no fundamental change to correct this, and future gains are speculative.)
Also as pointed out by someone else, swing trading isn't necessarily a good idea if you've been long more than a year and your shares now qualify for long-term capital gains.
This is not investing advice, just wanted to add some personal experience to the mix. Controlling risk by whatever means is important to keep stress levels low, or you can always set it and forget it. GLTA
Red day so far in the whole OTC.
At 15.4 million shares traded so far this week, this is on track to be the lowest volume week for ENZC since March of '20.
(I know we had the holiday on Monday - either way it's been a very quiet week for this ticker.)
Interesting info, thanks!
This is trading on 8% of the 30 day average volume so far today. Less than 1 million shares traded up to now. I bet it's shorts slowly covering since the next settlement date looks to be on the 31st and there's a market holiday in between.
Or I guess they'd have covered on yesterday's shakedown so maybe this is retail pushing back up with the reduced selling pressure.
Pretty near called it! Hopefully it goes up from here. :)
Having watched the video through, I have to heartily disagree with your claim.
I almost saved a copy, RIP. It was some good info and it's unfortunate it got privated.
Great interview, thanks for the link!
47:36 Here's the section talking about where they are now and what the next steps are to getting clone-3 to market.
35:46 Very interesting why Cotropia thinks big pharma hasn't targeted covid immutable sites yet.
To me, the science in the presentation looks solid, as long as there's not a false equivalence fallacy in play. Let me explain.
I'm using covid as the example, though the same analysis applies to Cotropia's work with HIV, rabies, etc. This is also intentionally oversimplified for brevity.
Cotropia's hypothesis seems to be:
- If the blood of donors, who've previously had covid or a demonstrable immune reaction to the mRNA vaccine, contains antibodies to covid peptides;
- And administering clone-3 causes a second group's blood samples to contain those same antibodies;
- Then clone-3 could stop the people in the second group from getting covid.
ie If the blood samples can be made to 'look the same' when measuring the antibodies to covid peptides, clone-3 may thus produce the same (or greater) levels of immunity to covid as recovering from covid or having an immune response to the mRNA vaccines.
That's a big assumption. What other processes are involved in the body's ability to produce and maintain antibodies to covid peptides? Are there any advantages or side effects to getting antibodies from clone-3 vs mRNA vaccine vs wild covid? Are there other intermediate reactions which might also play a role in conditioning the body to produce and accommodate the antibodies and make the immunity longer-lasting, rather than just the final presence of antibodies?
To borrow and repurpose a quote from the Wikipedia false equivalence examples:
"They're both living animals that metabolize chemical energy. Therefore there's little difference between having a pet cat and a pet jaguar."
"They're both blood samples that contain antibodies to covid peptides. Therefore there's little difference between having those antibodies from a natural recovery from covid, a vaccine induced immune response, or from clone-3."
The research process is also interesting to note. The part of that discussion I'm highlighting starts at 40:32 and runs until 44:05.
Cotropia and team collect blood samples and test B-cells from people who test positive for covid via PCR, or who have been vaccinated and shown symptoms (immune reaction), 14 days after acute symptoms have terminated. They screen the blood to determine if these people have a presence of antibodies to the known covid peptides.
People who have recovered from covid or been vaccinated and demonstrated an immune response, but who do not have the expected B-cells believed to show immunity to covid, are screened out by the researchers. But are these excluded people actually also covid immune? Or are any of the patients with B-cells actually not covid immune but assumed to be? In other words, it may be necessary but not sufficient to make covid antibody presence match in the sample groups, to provide the expected immunity against covid.
So it's very important to get to the primate studies/other animal studies "to see if the hypothesis is correct", as Cotropia puts it. We need to see that clone-3 has the intended effect and not that some overlooked factors are also necessary for lasting and effective immunity. It's also important to know there won't be any side effects since the focus for now is on presence of antibodies, not the method by which they got there.
Very cool technology either way and it's exciting to have this glimpse into the details!
Maybe it's only for Pinks, or maybe I've been using it wrong, lol. I've tried setting them before with no success.
OTCBB Securities Trading Rules
[...]
Only limit orders to buy, and limit or market orders to sell will be accepted. Limit orders may be specified as all-or-none, day, or good-till-canceled orders. No other types of orders for these securities will be accepted.
https://secure.tdameritrade.com/about/otcbb_disclaimer
A lot of major brokers like TD Ameritrade and Fidelity (and I think Schwab and eTrade) won't let retail traders set stop losses for OTC trades, afaik. But maybe MMs were clearing other investor groups' stop losses.
Another possibility is related to the short settlement date last Friday. MM's may have covered on low volume and accidentally pushed price higher than they wanted, and used tricks like gaps and laddered sells to short it back down into their desired price range today. (Basically fostering the right conditions for bears to rally, and nudging it along.)
Another possibility is some kind of share conversion and/or dilution. No way to know this until the next quarterly filing. There were some posts about it today. (See here and here.)
Parts of twitter were abuzz the last couple of week about The Stock Day podcast coinciding with a news drop. Didn't seem to get one (or I missed it?) so people might have sold the (non-)news.
Interesting day indeed!
44,504,388 shares traded today, which is 458% the 30 day average. I wonder what's up.
I'm having trouble pinning the action between trend lines. Not spotting much in the way of wedges or triangles. Seems very volatile. I do see a head & shoulders pattern from late April/early May followed by what might turn into an inverse head & shoulders after today, which would be bullish if it finished forming. Also triple-touched near the low which is interesting.
Daily chart below.
Legend:
-Dashed pink and light blue are bollinger bands and 20 period moving average line.
-Dark blue is 200 period moving average line.
-Pink circles on two gaps that got traded through today.
Good info, thank you!
Reeeeally low volume for that open. We've seen how fast they can pull this down on low volume, so without strong buying pressure I am guessing we'll see more red? I'm a little surprised there's not more activity after yesterday's action, maybe traders are still getting morning coffee, haha.
By weight, there were at least 42 bottles in the box Chandra showed us.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168801961
Assumedly they started with more than one box, but if they were only selling through OneLavi it may have been a OneLavi sized starting inventory (suitable for a few dozens of website hits/month). No way to know yet.
I'm waiting to see how the company pitches it - "sold out in minutes" sounds like the stuff of an incoming PR.
Agreed, though I think we still haven't quite seen the bottom. Am looking forward to the eventual bull trend when the pendulum finally swings back! I think ENZC will get a lot of attention if they can deliver major milestones in this timeframe.
That's a pleasant surprise! Looking forward to it. :)
I like the author's analysis that 2,300 people holding 1 million shares each would lock float. At today's close that'd be about $61k per investor.
Though Webull's 7 million account holders are demographically similar to those of its larger rival, with an average age of 40 and average account size of $4,000, they tend to be more active and more advanced investors, Denier told CNBC's "ETF Edge" on Monday.
https://www.cnbc.com/2021/12/02/webull-ceo-on-what-factors-differentiate-his-trading-platform-from-robinhood.html
Webull, ranked as the second most popular trading app worldwide with 2.7 million active users every month
https://www.businessamlive.com/robinhood-webull-etrade-etoro-double-global-users-to-14m-in-12-months/
Until the company delivers something concrete like a product on the market, or revenue, or a grant, or an uplist, this is a market for wolves. Retail is throwing money at this, which makes it profitable for the MM's or whoever to continue pulling the rug.
Charts: The head and shoulders on the hourly chart has fully materialized, and ENZC seem to be trending down accordingly. Short profit targets can be calculated using formulas on this page.
https://www.investopedia.com/terms/h/head-shoulders.asp
The H&S is slightly lopsided so I've put the neckline across .0667. Without a catalyst this could dip as low as the .03's and .04's in the short term, but any news could help to stave that off.
Interestingly, there was a .008 gap down on Monday, visible in the daily and weekly charts, which is good news for bulls since the market may want to play in the .070-.078 range some more.
Daily and intraweek weekly show rejection of the high bollinger band for now.
GLTA
Chart legend: pink dashed lines and bold blue 20 period moving average line are bollinger bands. Dark blue is 200 period moving average.
Hourly:
Daily
Intraweek weekly:
Well said!
I'm not totally sure why this moves so far down on so very little selling pressure, but it's a powerful deterrent to putting any new money in, speaking for myself.
I think things'll get better after IPF Immune reaches American retail. Might take a few months after that for all the gears to turn and company financials to reflect the activity.
Listing it on Wal Mart and Amazon marketplace storefronts ("shipped and sold by NPI" as a 3rd party seller) seems imminent. They have that deal with 1Lavi but I just checked and it's not listed there yet. The dedicated website is half-baked (no ecommerce!), but eventually we assume it'll list there too.
It makes sense they'd want some kind of inventory before listing in major places & announcing it to everyone. They'll clearly need more than 42 boxes to bring in noteworthy revenue.
I don't understand your other question. If you're asking about pricing, there seems to be enough demand just on twitter and ihub they could probably price it premium. Long way to go before they make millions, but a start is a start.
Do you have any date on the cost of these?
Hopefully they have more shipments on backorder! I'm counting 42 IPF Immune boxes total from that tweet.
The IPF Immune demo box is labeled 50 ml.
Shipping net weight from the tweet image is 2.10 kg = 4.63 lb = 74 oz = 2188 ml.
2188 ml divided by 42 units from the shipping label = 52 ml per unit.
I'd expect these to sell out instantly!
End of week chart matches up with the long term pattern shown in the prior post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168722668
Here's hoping we get news next week that shakes things up. The potential is there for a push to the high bollinger band around .115 with the right catalyst or market enthusiasm.
Weekly:
Here's everything I could find about ENZC's current liabilities and how they relate to this filing that says "there are no outstanding convertible debt pieces of ENZC common equity".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168639909
It's a lengthy and fairly technical read, but may have some answers for you. In a nutshell, it looks like there's a lot of old notes including convertible notes that are still most likely in play. We know from ENZC's latest filing (2021 amended financials) that there's an accumulated deficit of $29,533,234.
I don't think these financial liabilities are holding up the audit. This filing page 11 states "There are no disagreements with the auditing firm and the Company is working closely with all parties to finalize the audit." I don't think other types of "liabilities" (like fighting with Savov about shares) would be either - couldn't they just add a disclaimer and move foward. An uplisting to QB has new reporting requirements so the delay may be ENZC wanting to avoid those for the time being, since they seem to be in a period of rapid evolution, possible ongoing dilution, and behind the scenes dealmaking.